Abeona Therapeutics (ABEO) vs Indaptus Therapeutics (INDP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Abeona Therapeutics (ABEO) has outperformed Indaptus Therapeutics (INDP) over the past year, losing 3.2% versus a loss of 38.8%. Over five years, ABEO leads with a -77.7% price change compared with -99.0% for INDP. Indaptus Therapeutics is the larger company by market cap ($301.1 million vs $290.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | INDP |
|---|---|---|
| Share price | $5.08 | $2.26 |
| Market cap | $290.49M | $301.13M |
| 1-day change | +1.40% | -12.74% |
| YTD return | -3.61% | -22.34% |
| 1-year return | -3.24% | -38.75% |
| 5-year return | -77.67% | -98.97% |
| EPS (TTM) | $-1.18 | $-6.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.65 | $5.96 |
| 52-week low | $4.00 | $0.92 |
| Distance from 52-week high | -33.59% | -62.08% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +271.65% | — |
| Average volume | 1.42M | 832.95K |
| Shares outstanding | 57.18M | 133.24M |
| Employees | 226 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABEO has outperformed INDP by 35.5 percentage points over the past year.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Healthcare · Biotechnology · 226 employees
About Indaptus Therapeutics
INDP stock →Indaptus Therapeutics, Inc., a clinical biotechnology company, engages in the development of various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors.
Healthcare · Biotechnology · 5 employees
ABEO vs INDP FAQ
Which is bigger, Abeona Therapeutics or Indaptus Therapeutics?
Indaptus Therapeutics (INDP) is larger, with a market capitalization of $301.13M compared with $290.49M for Abeona Therapeutics (ABEO).
Which stock has performed better over the past year, ABEO or INDP?
ABEO returned -3.24% over the past 12 months, compared with -38.75% for INDP (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and Indaptus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.